Paul Williamson, M.D.
Dr. Paul Williamson earned his B.S and M.D. from the University of Massachusetts. He completed a medical residency at the St. Vincent Hospital in Worcester and a rheumatology fellowship at the Hospital of the University of Pennsylvania in Philadelphia, later becoming Chief of Medicine at the Union Hospital Campus of the North Shore Medical Center.
Dr. Williamson joined Johnson & Johnson in 2001 where he worked with Centocor R&D leading the Neurology/Ophthalmology Clinical Team and where he led the clinical program resulting in marketing authorization for infliximab in ankylosing spondylitis. He managed early clinical development responsibilities for several new molecular entities in a number of therapeutic areas, including expedited development of fully human anti-TNF in non-infectious uveitis through Phase 2, and the development of new technologies/devices for subcutaneous self-administration of Centocor's biological products.
He subsequently served as Executive Director of Clinical Development at Therakos, with responsibilities for all clinical functional areas. In 2007 Dr. Williamson moved to Johnson & Johnson’s Stem Cell Internal Venture. As Senior Director, he was responsible for clinical development and served as product development team leader for an allogeneic cell-based product being developed for retinal degeneration. There he had oversight responsibility for all components of development, including innovative surgical procedures.
In 2014 Dr. Williamson left Johnson & Johnson with a personal mission to pursue development of and investment in early stage technologies that satisfy unmet medical needs.